6Suppliers
2Customers
2Debt Items
11Related Chains

LB Pharmaceuticals Inc Suppliers

TickerNameConfidenceEvidence
EXTERNAL-VENDORS-AND-CROS EXTERNAL-VENDORS-AND-CROS 90% This model includes internal teams and systems as well as external vendors and CROs to comprise a full clinical trial team.
THIRD-PARTIES THIRD-PARTIES 85% We also rely on third parties to provide other products, services, parts, or otherwise to operate our business, including with respect to our cybersecurity infrastructure.
ANDREW-VAINO ANDREW-VAINO 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
ANDREW-VAINO-PH-D ANDREW-VAINO-PH-D 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
MARC-PANOFF MARC-PANOFF 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
ZACHARY-PRENSKY ZACHARY-PRENSKY 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…

LB Pharmaceuticals Inc Customers

TickerNameConfidenceEvidence
LICENSEES-OF-LB-102 LICENSEES-OF-LB-102 90% Net sales are defined in these agreements as the gross payments received on total commercial sales of LB-102 less certain standard deductions, whether received by us or any licensee of LB-102.
HOLDERS-OF-FUTURE-ROYALTIES HOLDERS-OF-FUTURE-ROYALTIES 80% As of March 31, 2026, certain of our former and current officers and their affiliates held 1.13% of the future royalties.

LB Pharmaceuticals Inc Debt Obligations

InstrumentDescriptionConfidenceEvidence
LBRX-DEBT Debt stack $3.5M 90% Market cache reports total debt of $3.5M.
LBRX-DEBT-10624 Warrants outstanding: 247000 90% xbrl warrant detail from xbrl 2025-12-31.

LB Pharmaceuticals Inc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for LB Pharmaceuticals Inc.

LB Pharmaceuticals Inc Ownership

HolderNameConfidenceEvidence
LBRX-OWNER-DEEP-TRACK-CAPITAL-LP Deep Track Capital, LP 90% 13F overlay lists Deep Track Capital, LP as top holder; 77 tracked holders.

LB Pharmaceuticals Inc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
EH EHang Holdings Limited 100.00 2
ABT Abbott Laboratories 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
EM Smart Share Global Limited 100.00 2
JNJ Johnson & Johnson 100.00 2
PRE Prenetics Global Limited 100.00 2
SNYNF Sanofi 100.00 2
SBMFF Sino Biopharmaceutical Limited 100.00 2
NMRA Neumora Therapeutics, Inc. 100.00 2
NBP NovaBridge Biosciences 36.29 1 ['spend']